BeOne raises 2026 revenue outlook after Q3 growth

BeOne Medicines said third-quarter total revenue rose 34% from a year earlier to $1.9 billion and raised its full-year 2026 revenue guidance.

The oncology company said BRUKINSA global revenue reached $1.4 billion in the quarter, also up 34% from the prior-year period. It reported GAAP net income of $385 million, compared with $125 million a year earlier.

BeOne reported diluted GAAP earnings of $3.28 per American Depositary Share and non-GAAP diluted earnings of $4.59 per ADS for the quarter.

The company raised its 2026 total revenue guidance to $6.9 billion to $7.0 billion, from a previous range of $6.6 billion to $6.8 billion. It also raised guidance for GAAP operating income to $1.2 billion to $1.3 billion and non-GAAP operating income to $1.9 billion to $2.0 billion.

BeOne said third-quarter product revenue totalled $1.9 billion, with TEVIMBRA global sales of $243 million and Amgen in-licensed product sales of $167 million. It said research and development expenses and selling, general and administrative expenses both increased from a year earlier.

The company said its earnings call would be webcast on November 5, 2026.